Abbott Vascular: The Now-Ready-For-Prime-Time Player
Executive Summary
Four years ago, lured into a mainstream cardiovascular business by the promise of drug-eluting stents, Abbott set about revamping its medical products business in an effort to create a device business that would rival its pharmaceutical business in financial returns. What was at first a niche strategy, aimed at bringing small, but interesting technologies to interventionalists, has become a more broad-based play that, company officials hope, will place them among the leaders in vascular devices.
You may also be interested in...
Ireland's Medtech Explosion
Over the last three decades, Ireland has built a robust medical device community serving large multi-national device companies, built on favorable tax policies and a strong manufacturing and engineering base. But now Ireland is trying to incubate a robust start-up community as well, focused on R&D and innovation, hoping to create the next Medtroniic or Covidien rather than simply serving the current ones.
Ireland's Medtech Explosion
Over the last three decades, Ireland has built a robust medical device community serving large multi-national device companies, built on favorable tax policies and a strong manufacturing and engineering base. But now Ireland is trying to incubate a robust start-up community as well, focused on R&D and innovation, hoping to create the next Medtroniic or Covidien rather than simply serving the current ones.
Abbott Ventures: Building A Venture Portfolio in Devices
Corporate venture investing has become an increasingly important source of capital as traditional venture firms remained squeezed. In devices, the latest entrant into the field is Abbott Ventures, which sees itself as an extension of Abbott's internal efforts to build its device pipeline, favoring mid-stage deals in technology and therapeutic areas that fit strategically with Abbott's existing device businesses.